Male (n (%)) | 447 (65) | | 165 (63) | |
Large duct PSC (n (%)) | 630 (91) | | 231 (88) | |
Age at diagnosis PSC (years) (median (IQR)) | 37 (27–49) | | 45 (33–57) | |
AIH overlap (n (%)) | 37 (5) | | 5 (2) | |
IBD (n (%)) | 480 (70) | | 195 (74) | |
UC (n (%)) | 373 (54) | | 143 (54) | |
Crohn’s disease (n (%)) | 89 (13) | | 39 (15) | |
Unspecified (n (%)) | 18 (3) | | 13 (5) | |
Ursodeoxycholic acid (n (%))* | 326 (80) | 281 (41) | | |
Follow-up time (months) (median (IQR)) | 110 (69–184) | | 103 (53–153) | |
PSC-related death (n (%)) | 71 (10) | | 37 (14) | |
Liver transplantation (n (%)) | 121 (18) | | 18 (7) | |
Alkaline phosphatase (xULN) (median (IQR)) | 1.97 (1.43–3.28) | 255 (37) | 2.27 (1.27–3.83) | 177 (67) |
Aspartate aminotransferase (xULN) (median (IQR)) | 1.55 (1.0–3.03) | 169 (24) | 1.21 (0.79–2.05) | 198 (75) |
Alanine aminotransferase (xULN) (median (IQR)) | 2.29 (1.34–4.66) | 268 (39) | 1.40 (0.88–2.58) | 238 (90) |
Bilirubin (xULN) (median (IQR)) | 0.82 (0.53–1.71) | 208 (30) | 0.71 (0.47–1.29) | 178 (67) |
Gamma-glutamyl transpeptidase (xULN) (median (IQR)) | 6.11 (3.36–11.88) | 282 (41) | 7.15 (1.98–14.30) | 210 (80) |
Albumin (xLLN) (median (IQR)) | 1.14 (1.02–1.23) | 312 (45) | 1.23 (1.11–1.31) | 182 (69) |
Platelets (xLLN) (median (IQR)) | 1.79 (1.36–2.29) | 375 (54) | 1.89 (1.53–2.75) | 189 (71) |
AIH, autoimmune hepatitis; PSC, primary sclerosing cholangitis; xLLN, lower limit of normal; xULN, upper limit of normal. |